Deutsche Bank analyst Steve Powers maintains Keurig Dr Pepper (NASDAQ:KDP) with a Hold and raises the price target from $38 to $39.
Crinetics Announced Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that paltusotine, an oral, once-daily investigational compound, achieved positive results by meeting the primary endpoint and all secondary endpoints of the
